Back to top
more

CRISPR Therapeutics (CRSP)

(Real Time Quote from BATS)

$47.79 USD

47.79
644,590

-1.06 (-2.17%)

Updated Aug 16, 2024 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat

by Zacks Equity Research

CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 0% and 8.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -550% and 72.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.

Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.

Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.13, moving +0.99% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $51.08 in the latest trading session, marking a -1.79% move from the prior day.

Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

by Zacks Equity Research

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.

Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth

by Zacks Equity Research

Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.

GSK Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

VYNE Gains on Preclinical Data for IPF Candidate

by Zacks Equity Research

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio

by Zacks Equity Research

Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.

Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

by Zacks Equity Research

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

by Zacks Equity Research

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

by Zacks Equity Research

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $50.31 in the latest trading session, marking a -0.49% move from the prior day.

Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

by Zacks Equity Research

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

Is BioRad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

by Zacks Equity Research

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.

Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data

by Zacks Equity Research

Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.

Humacyte (HUMA) Completes Enrollment in HAV Technology Study

by Zacks Equity Research

Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.